相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Viral, immunologic, and clinical features of primary effusion lymphoma
Kathryn Lurain et al.
BLOOD (2019)
Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
David A. Davis et al.
ONCOIMMUNOLOGY (2019)
Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma
Ajinkya Patil et al.
BLOOD ADVANCES (2019)
CK1 alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma
Ajinkya Patil et al.
BLOOD (2018)
HIV-Associated Cancers and Related Diseases
Robert Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD
T. Yuan et al.
LEUKEMIA (2017)
T-cell responses to KSHV infection: a systematic approach
Romin Roshan et al.
ONCOTARGET (2017)
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
R. Gopalakrishnan et al.
ONCOGENE (2016)
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Richard J. Jones et al.
CLINICAL CANCER RESEARCH (2016)
Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study
Mark N. Polizzotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
Maria Pia Abruzzese et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Primary B Lymphocytes Infected with Kaposi's Sarcoma-Associated Herpesvirus Can Be Expanded In Vitro and Are Recognized by LANA-Specific CD4+ T Cells
Samantha M. Nicol et al.
JOURNAL OF VIROLOGY (2016)
IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4+ T-cell responses
Estefania Nova-Lamperti et al.
SCIENTIFIC REPORTS (2016)
Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT NOT DENDRITIC CELLS
Sharad K. Mittal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
Cinzia Fionda et al.
ONCOTARGET (2015)
Pomalidomide: Evaluation of Cytochrome P450 and Transporter-Mediated Drug-Drug Interaction Potential In Vitro and in Healthy Subjects
Claudia Kasserra et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinase-Dependent Upregulation of CD86 on B Cells
Kesley Attridge et al.
JOURNAL OF IMMUNOLOGY (2014)
Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature
A. Antar et al.
BLOOD CANCER JOURNAL (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Identification of Host-Chromosome Binding Sites and Candidate Gene Targets for Kaposi's Sarcoma-Associated Herpesvirus LANA
Fang Lu et al.
JOURNAL OF VIROLOGY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
The ubiquitin system and Kaposi's sarcoma-associated herpesvirus
Akira Ashizawa et al.
FRONTIERS IN MICROBIOLOGY (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation
Lina E. Tze et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation
Michael Haidinger et al.
JOURNAL OF IMMUNOLOGY (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
Georg Aue et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy
Pablo Schierloh et al.
INFECTION AND IMMUNITY (2007)
Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma
Florian Bihl et al.
AIDS (2007)
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-θ activation and enhancing the DNA-binding activity of AP-1 but not NF-κB, OCT-1, or NF-AT
F Payvandi et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Defective immune function of primary effusion lymphoma cells is associated with distinct KSHV gene expression profiles
TJ Suscovich et al.
LEUKEMIA & LYMPHOMA (2004)
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
PH Schafer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
A differential requirement for phosphoinositide 3-kinase reveals two pathways for inducible upregulation of major histocompatibility complex class II molecules and CD86 expression by murine B lymphocytes
S Marshall-Clarke et al.
IMMUNOLOGY (2003)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4
EK Kapsogeorgou et al.
JOURNAL OF IMMUNOLOGY (2001)
Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus
C Brander et al.
JOURNAL OF IMMUNOLOGY (2000)
Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis
L Coscoy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Activity of thalidomide in AIDS-related Kaposis's sarcoma
RF Little et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins
S Ishido et al.
JOURNAL OF VIROLOGY (2000)
Inhibition of natural killer cell-mediated cytotoxicity by kaposi's sarcoma-associated herpesvirus K5 protein
S Ishido et al.
IMMUNITY (2000)
分享论文
